RSS
aflibercept
Mylan & Momenta Pharmaceuticals announce strategic development of biosimilar to aflibercept
A strategy for the development of a biosimilar to the vascular endothelial growth factor (VEGF) inhibitor treatment for various degenerative retinal diseases, aflibercept, has been announced by Momenta Pharmaceuticals and Mylan. more
